Single-Dose Psilocybin Treatment for Major Depressive Disorder

Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research Landscape

(2023) Sarah McNamee et al.   JAMA Psychiatry

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

(2022) Natalie Gukasyan et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Clinical research challenges posed by difficult-to-treat depression

(2022) A. John Rush et al.   PSYCHOLOGICAL MEDICINE

Antidepressants and health-related quality of life (HRQoL) for patients with depression: Analysis of the medical expenditure panel survey from the United States

(2022) Omar A. Almohammed et al.   PLoS One

Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials

(2022) Jacob S. Aday et al.   PSYCHOPHARMACOLOGY

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

(2022) Joost J Breeksema et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

(2022) Guy M. Goodwin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is good science leading the way in the therapeutic use of psychedelic drugs?

(2022) Wayne D. Hall et al.   PSYCHOLOGICAL MEDICINE

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder

(2022) Michael P. Bogenschutz et al.   JAMA Psychiatry

Preparing for the Bursting of the Psychedelic Hype Bubble

(2022) David B. Yaden et al.   JAMA Psychiatry

Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database

(2022) Chiara Gastaldon et al.   DRUG SAFETY

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

(2022) Robin von Rotz et al.   EClinicalMedicine

Trial of Psilocybin versus Escitalopram for Depression

(2021) Robin Carhart-Harris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults

(2021) Brett D. M. Jones et al.   JAMA Network Open

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer

(2020) Gabrielle I Agin-Liebes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

(2020) Alan K. Davis et al.   JAMA Psychiatry

Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature

(2018) Timothy I. Michaels et al.   BMC Psychiatry

Unknown

(2018)   DEPRESSION AND ANXIETY

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

(2017) R. L. Carhart-Harris et al.   PSYCHOPHARMACOLOGY

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

(2016) Roland R Griffiths et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

(2016) Stephen Ross et al.   JOURNAL OF PSYCHOPHARMACOLOGY

A critical review of pharmacotherapy for major depressive disorder

(2011) Jamie M. Dupuy et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

(2010) Charles S. Grob et al.   ARCHIVES OF GENERAL PSYCHIATRY

The Future of Psychopharmacology of Depression

(2010) Trina Chang et al.   JOURNAL OF CLINICAL PSYCHIATRY

Human hallucinogen research: guidelines for safety

(2008) MW Johnson et al.   JOURNAL OF PSYCHOPHARMACOLOGY